Complications from preterm birth, especially due to lung disease, are the leading cause of neonatal mortality and an important contributor to child and adult morbidities. Improved neonatal care has shifted the survival of premature infants from 32 weeks gestational age (GA) in the presurfactant era to the current lower limit of 23 weeks GA; however, extreme prematurity (23-29 weeks GA) has an increased respiratory morbidity that persists into childhood (1, 2). The complex origins of adult respiratory disease can often be traced back to the fetal and early childhood period when the lung is undergoing rapid development.
Proteomic Profiles Associated with Early Echocardiogram Evidence of Pulmonary Vascular Disease in Preterm Infants
Complications from preterm birth, especially due to lung disease, are the leading cause of neonatal mortality and an important contributor to child and adult morbidities. Improved neonatal care has shifted the survival of premature infants from 32 weeks gestational age (GA) in the presurfactant era to the current lower limit of 23 weeks GA; however, extreme prematurity (23-29 weeks GA) has an increased respiratory morbidity that persists into childhood (1, 2) . The complex origins of adult respiratory disease can often be traced back to the fetal and early childhood period when the lung is undergoing rapid development.
In addition to airways and parenchymal disease, preterm infants often have early pulmonary vascular disease (PVD), as defined by abnormal vascular growth and function (3) . Strong laboratory and clinical data show that early disruption of pulmonary vascular growth (angiogenesis) impairs alveolarization, leading to a reduced surface area and a high risk for PVD (4, 5) . Our recent clinical studies showed that abnormal echo findings consistent with PVD at postnatal Day 7 were strongly associated with the subsequent diagnosis and severity of bronchopulmonary dysplasia (BPD), the need for supplemental oxygen therapy, and later signs of PVD at 36 weeks corrected age (5) .
Moreover, we do not fully understand why some preterm infants develop respiratory problems while others do not. The structural development of the human lung is dependent upon numerous growth factors and complex pathways, including angiogenic signaling. A better understanding of the underlying proteomic profiles may help to explain the heterogeneity across infants and could serve as biomarkers to identify those at highest risk for adverse events. An aptamer-based proteomic platform was shown to be useful in several recent studies of other diseases (6) (7) (8) (9) . This new technology has the ability to measure proteins (including low-abundance proteins) over a large dynamic range and provides a unique opportunity to study a large number of proteins (n = 1,121) using a small amount of blood (only 50 ml of plasma), which is essential in studies of preterm infants.
We performed a prospective study of preterm infants with circulating blood samples collected at z7 days of age. A machine learning approach was applied to protein measurements obtained using a novel aptamer-based proteomics technology. This preliminary evaluation identified proteins associated with echocardiographic evaluations of early PVD.
Methods
All data were prospectively obtained as part of an observational research study that included subjects who were enrolled between July 2006 and March 2012 at hospitals affiliated with two academic institutions (University of Colorado School of Medicine and Indiana University School of Medicine). The protocol was approved by the institutional review board of each participating site, and written informed consent was received from the parents or guardians of all participants. Research echocardiograms were standardized at both sites before initiation of the study and were performed in subjects at 7 days of age. All echocardiograms were interpreted by a single cardiologist who remained masked to the subjects' clinical status to ensure consistent evaluations of the findings. The criteria for enrollment and PVD determination have been published previously (5) .
We prospectively collected blood samples at Day 7 (6 48 h) from 100 infants during their first week after birth. Plasma samples were collected using an ethylenediaminetetraacetic acid plasma tube and centrifuged after phlebotomy. The supernatant was removed, aliquoted, and placed in a freezer at 280 8 C. At the conclusion of the study, a proteomic analysis was conducted on an aliquot using the SOMAscan assay at the laboratories of SomaLogic, Inc. The SOMAscan proteomic assay is described in detail elsewhere (10) .
Random forests of 5,000 classification trees were made using the randomForest package in RStudio (RStudio Team 2015, RStudio, Inc.; http://www.rstudio.com/) to assess relationships between proteins and PVD. Area-under-the-curve random forests (AUCRF) were made using the AUCRF package to iteratively eliminate the lowest-ranked proteins from a random forest and calculate the area under the forest's receiver operating characteristic curve to determine the number of proteins that created the most efficient classifier. The subset of only the 18 top-ranked proteins (as determined by AUCRF) was then used to create the final random forest.
Results
The cohort was comprised of 100 preterm infants, 44 of whom were diagnosed with PVD at Day 7. Across the PVD and non-PVD groups, there was no difference in GA (mean, 26 weeks for both groups), sex (females 43% vs. 57%), or birthweight z-score (mean, 20.3 for both groups). Clinical status varied with regard to BPD at 36 weeks, and cesarean section delivery also did not differ between groups.
The protein selection process, based on the out-of-bag area under the curve (c-index), resulted in the selection of 18 proteins with the highest area under the curve of 0.82. These 18 proteins had a classification error rate of 24% and discriminated well between those who developed and those who did not develop PVD. A brief description of these 18 proteins is provided in Table 1 , and for a subset of proteins, the association with PVD is graphically displayed in Figure 1 .
Discussion PVD has been identified as a risk factor for later respiratory disease, and there is interest in identifying potential biomarkers associated with early PVD. In this preliminary investigation, we identified 18 biomarkers associated with PVD at Day 7 in a cohort of 100 preterm infants.
Several of the identified proteins have known or probable associations with pulmonary outcomes, and several selected proteins were related to extracellular matrix, growth factors, and angiogenesis (ON [osteonectin] 
Longitudinal Assessment of Children with Mild Cystic Fibrosis Using Hyperpolarized Gas Lung Magnetic Resonance Imaging and Lung Clearance Index
To the Editor:
With improving life expectancy in patients with cystic fibrosis (CF) and annual rates of decline in FEV 1 as low as 1-2% predicted per year (1), the value of spirometry as a measurement of longitudinal change is limited. Spirometry is also insensitive to early changes in the CF lung, and the lung clearance index (LCI) derived from multiple breath washout (MBW) has emerged as a promising alternative for patients with well-preserved spirometry, including children (2). Recent studies have highlighted the potential of LCI for the longitudinal assessment of CF lung disease (3), although there are still questions regarding the mechanisms behind the mixed LCI response seen in intervention studies (4) (5) (6) . As a global metric, however, LCI offers little information as to the location of any abnormality and the associated pathophysiology.
Hyperpolarized gas ventilation magnetic resonance imaging (ventilation MRI) is a sensitive imaging technique that reveals the distribution of ventilation within the lung in exquisite detail, allowing regional ventilation heterogeneity to be assessed. Ventilation MRI has been shown to be highly sensitive to early lung function abnormalities in CF and other obstructive airways diseases before changes are manifested in spirometry (7) (8) (9) .
In a previous study, we reported cross-sectional data from a cohort of 19 children with mild CF lung disease (8) . In that study, ventilation MRI demonstrated lung defects when abnormality was often not detectable by either computed tomography or LCI. Our aim in the present study was to reassess these children at a second time point 1-2 years after the baseline visit and describe any observed longitudinal changes in lung function or ventilation MRI. Some of the results of these studies have been previously reported in the form of abstracts (10) (11) (12) .
Methods
Fourteen children with CF from the previously described cohort (8) were reassessed at a second time point between 1.3-2.0 years after baseline using helium-3 ( 3 He) ventilation MRI, MBW, spirometry, and body plethysmography as previously described (8) . The patients were clinically stable (free from exacerbation and needing no new treatments) for at least 4 weeks before both visits and were on stable chronic medical regimens according to national guidelines. Two indices were calculated from the ventilation images: (1) the ventilation defect percentage (VDP), which quantifies the fraction of the lung volume that is not ventilated, and (2) the mean coefficient of variance of ventilated image signal intensity (CV mean ), which is a metric of ventilation heterogeneity.
The percentage change (D) from baseline to visit 2 was calculated for all metrics. The Wilcoxon matched-pairs signed-rank test and Spearman correlations were performed owing to the small sample size. Definition of abbreviations: CV mean = mean coefficient of variance of ventilated image signal intensity; LCI = lung clearance index; RV = residual volume; S acin = ventilation heterogeneity arising from intraacinar airways; S cond = ventilation heterogeneity arising from conducting airways; TLC = total lung capacity; VDP = ventilation defect percentage. Data are mean (SD). P values from the Wilcoxon signed-rank test are given for baseline and visit 2 group comparison.
